OncoCipherPATIENT
Educational & Guideline Reference Notice: Unranked FDA-label and national guideline option categories and recruiting clinical trials for discussion with a licensed oncologist. Protocol drug dosing and autonomous treatment prescriptions are excluded.

← Colorectal Cancer (CRC) Overview

Colorectal Cancer (CRC) — All 34 Unranked Reference Options

Provenance SHA-256: 80ed92210198ee05 · Protocol drug dosing hard-excluded in Patient Edition.

Option / Regimen FamilyCategory & StatusCurated Source IDs
Stage 0/I colon local treatment review
Confirm endoscopic/pathological features and definitive local management.
care_pathway
Guideline/evidence discussion; institutional protocol and current-label review required.
NCI-COLON
Stage II colon observation discussion
Routine adjuvant chemotherapy is not recommended in the absence of a high-risk subgroup.
care_pathway
Guideline/evidence discussion; institutional protocol and current-label review required.
NCI-COLON, pdq_colon
Stage II colon adjuvant risk/benefit review
Discuss adjuvant treatment; T4 and other high-risk findings have different recommendation strength.
conventional_therapy
Guideline/evidence discussion; institutional protocol and current-label review required.
NCI-COLON, pdq_colon, FDA-DPD, FDA-XELODA-2025, xeloda
Stage II dMMR colon specialist review
Do not routinely offer adjuvant chemotherapy solely because stage II disease is present; high-risk cases require individual review.
care_pathway
Guideline/evidence discussion; institutional protocol and current-label review required.
NCI-COLON, pdq_colon
Stage III colon FOLFOX / CAPOX review
Discuss oxaliplatin plus fluoropyrimidine adjuvant therapy following resection.
conventional_therapy
Guideline/evidence discussion; institutional protocol and current-label review required.
FDA-DPD, FDA-XELODA-2025, LABEL-OXALIPLATIN, NCI-COLON, pdq_colon, pm_29590544, pm_29611518, oxaliplatin
Stage 0/I rectal local treatment review
Determine whether local excision or oncologic resection is appropriate.
care_pathway
Guideline/evidence discussion; institutional protocol and current-label review required.
NCI-RECTAL
Locally advanced rectal total neoadjuvant therapy review
Discuss total neoadjuvant therapy (induction vs consolidation chemotherapy; long-course CRT vs short-course RT) before restaging and local management.
conventional_therapy
NCI PDQ and prospective randomized trials (OPRA, RAPIDO, UNICANCER-PRODIGE 23); institutional protocol and current component-label review required.
NCI-RECTAL, pdq_rectal, pm_35483010, pm_37883738, pm_33301740, pm_33862000, FDA-DPD, FDA-XELODA-2025
Lower-risk locally advanced rectal selective-radiation discussion
In cT2N+, cT3N-, or cT3N+ sphincter-sparing candidates, neoadjuvant FOLFOX with selective pelvic chemoradiotherapy (reserved for <20% primary tumor decrease or FOLFOX intolerance) was noninferior to preoperative CRT for 5-year DFS (80.8% vs 78.6%, HR 0.92).
care_pathway
Prospective randomized phase 3 trial PROSPECT (NCT01515787; PMID 37272534) and NCI PDQ rectal treatment summary.
NCI-RECTAL, pdq_rectal, pm_37272534, FDA-DPD, LABEL-OXALIPLATIN
Dostarlimab (JEMPERLI) for MSI-H or dMMR stage II/III locally advanced rectal cancer
Discuss single-agent dostarlimab (JEMPERLI §1.2) with the rectal multidisciplinary team.
biomarker_selected_therapy
Rectal multidisciplinary team discussion.
LABEL-JEMPERLI-2026-10, pdq_rectal
Rectal complete-response organ-preservation discussion
Watch-and-wait organ preservation discussion for clinical complete response or near-complete response after TNT under structured endoscopic, DRE, and pelvic MRI surveillance, with salvage TME for local regrowth (5-yr DFS after TME at restaging vs TME at regrowth 64% vs 64% in OPRA).
care_pathway
Prospective phase 2 OPRA trial (NCT02008656; PMID 35483010, PMID 37883738) and NCI PDQ rectal treatment summary.
NCI-RECTAL, pdq_rectal, pm_35483010, pm_37883738
Potentially curable metastatic local-treatment review
Multidisciplinary hepatobiliary/thoracic surgical and local-therapy review at baseline and restaging (~2-month intervals during conversion systemic therapy to limit chemotherapy-associated steatohepatitis/sinusoidal injury).
care_pathway
Guideline/evidence discussion; institutional protocol and current-label review required.
NCI-COLON, pdq_colon, pdq_rectal
Pembrolizumab first-line review
Selected molecular and treatment-setting conditions match the approval context.
biomarker_selected_therapy
FDA CRC first-line approval; complete current label review required.
FDA-PD1
Nivolumab + ipilimumab review
Selected MSI-H/dMMR metastatic conditions match the approval context; trial evidence is immunotherapy-naive.
biomarker_selected_therapy
FDA 2025 CRC approval; software scope is adult metastatic, immunotherapy-naive discussion.
FDA-NIVO-IPI, opdivo
FOLFOX / FOLFIRI + anti-VEGF review
Discuss a chemotherapy doublet strategy with anti-VEGF treatment where appropriate.
conventional_therapy
Guideline/evidence discussion; institutional protocol and current-label review required.
NCI-COLON, pdq_colon, avastin, FDA-DPD, FDA-XELODA-2025, LABEL-BEVACIZUMAB, LABEL-IRINOTECAN, LABEL-OXALIPLATIN
Left-sided RAS/BRAF-wild-type doublet + anti-EGFR review
The first-line anti-EGFR discussion is restricted to reviewed RAS wild type and left-sided primary. This preferred anti-EGFR doublet pathway requires both RAS and BRAF wild type; this does not exclude cetuximab within BRAF-targeted combinations.
biomarker_selected_therapy
Guideline/evidence discussion; institutional protocol and current-label review required.
NCI-COLON, pdq_colon, erbitux, vectibix, pm_35666229, FDA-DPD, FDA-XELODA-2025, LABEL-IRINOTECAN
Encorafenib + cetuximab + fluorouracil-based chemotherapy review
The 2026 approval includes fluorouracil-based chemotherapy; BREAKWATER studied treatment-naive disease.
biomarker_selected_therapy
FDA traditional approval February 24, 2026: adult BRAF V600E mCRC with cetuximab and fluorouracil-based chemotherapy; no treatment-naive restriction in section 1.2. Evidence population applicability is reported separately.
FDA-BRAF-2026, FDA-DPD, FDA-XELODA-2025, LABEL-BRAFTOVI-2026, LABEL-IRINOTECAN, LABEL-OXALIPLATIN
Encorafenib + cetuximab after prior therapy
FDA section 1.2 separately indicates encorafenib plus cetuximab after prior therapy for BRAF V600E metastatic CRC.
biomarker_selected_therapy
FDA indication after prior therapy; distinct from the chemotherapy-containing regimen and its BREAKWATER population.
FDA-BRAF-2026, FDA-DPD, LABEL-BRAFTOVI-2026
Tucatinib + trastuzumab review
Review after progression following the three specified chemotherapy backbones.
biomarker_selected_therapy
FDA accelerated approval; confirm current status and full labels.
FDA-HER2, LABEL-TUKYSA-2026-10
Sotorasib + panitumumab review
Specified prior chemotherapy and exact KRAS variant are required.
biomarker_selected_therapy
FDA sotorasib plus panitumumab approval for adult KRAS G12C metastatic CRC after the specified prior chemotherapy. The indication does not explicitly require progression; prior therapy alone does not establish progression. This option does not inherit the separate adagrasib plus cetuximab CRC regulatory status.
FDA-KRAS-SOTO
Adagrasib + cetuximab — historical CRC indication
Historical CRC trial and approval criteria are retained for traceability. They do not establish current approval or eligibility.
biomarker_selected_therapy
No current FDA approval in colorectal cancer. Current KRAZATI label (SPL version 14, effective 2026-08-31), Recent Major Changes: “KRAS G12C Mutated Locally Advanced or Metastatic Colorectal Cancer - Accelerated Approval Indication Removed 08/2026”; its only indication is KRAS G12C-mutated non-small cell lung cancer (§1). FDA lists the withdrawal on September 1, 2026. Historical criteria and KRYSTAL-1 results are kept as study evidence only.
FDA-KRAS-ADA, FDA-KRAS-ADA-WITHDRAWAL, LABEL-KRAZATI-2026-08, LABEL-KRAZATI-SPL-14
Trifluridine/tipiracil + bevacizumab review
Prior exposure requirements include anti-EGFR when RAS wild type.
conventional_therapy
FDA approved combination; exact full-label eligibility and safety review required.
FDA-FTD-BEV, LABEL-BEVACIZUMAB
Fruquintinib review
Anti-EGFR exposure is required for RAS wild type when medically appropriate.
conventional_therapy
FDA approved refractory metastatic CRC context.
FDA-FRUQ
CRC surveillance and survivorship review
Review an individualized post-treatment surveillance plan.
care_pathway
Guideline/evidence discussion; institutional protocol and current-label review required.
NCI-COLON, NCI-RECTAL
FOLFOXIRI + bevacizumab first-line triplet review (TRIBE / TRIBE2)
Higher response rate and longer PFS/OS vs FOLFIRI + bevacizumab in TRIBE (ECOG 0-2 age 18-70 or ECOG 0 age 71-75).
conventional_therapy
FDA first-line fluoropyrimidine-irinotecan/oxaliplatin + bevacizumab label coverage; triplet studied in TRIBE/TRIBE2.
pm_25337750, pm_32164906, avastin, oxaliplatin, camptosar, FDA-DPD
Capecitabine (XELODA) monotherapy first-line review
Oral fluoropyrimidine option when combination chemotherapy is not preferred.
conventional_therapy
FDA-approved single-agent mCRC indication when fluoropyrimidine therapy alone is preferred (XELODA section 1.1).
xeloda
Capecitabine + bevacizumab first-line low-intensity review (AVEX)
Prolonged PFS vs capecitabine alone in older patients unsuitable for oxaliplatin/irinotecan doublets (AVEX).
conventional_therapy
Prospective phase 3 trial support (AVEX, age >=70 not candidates for oxaliplatin/irinotecan); AVASTIN section 1.1 names intravenous fluorouracil-based chemotherapy (clinician review required for oral capecitabine pairing).
pm_24028813, xeloda, avastin
Fluoropyrimidine + bevacizumab maintenance / oxaliplatin stop-and-go review (CAIRO3 / OPTIMOX1)
Maintains disease control after induction while pausing oxaliplatin cumulative sensory neuropathy.
conventional_therapy
Prospective phase 3 maintenance/de-escalation trials after non-progressing oxaliplatin induction (CAIRO3, OPTIMOX1).
pm_25862517, pm_16421419, xeloda, avastin, FDA-DPD
Second-line switched doublet (FOLFOX or FOLFIRI) + bevacizumab review (ML18147 / E3200)
Overall survival and PFS improvement over switched chemotherapy alone in ML18147 and E3200.
conventional_therapy
FDA-approved second-line mCRC with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin after progression on first-line bevacizumab-containing regimen (ML18147) or without prior bevacizumab (E3200).
avastin, oxaliplatin, camptosar, FDA-DPD
Ziv-aflibercept (ZALTRAP) + FOLFIRI second-line review (VELOUR)
Improved OS, PFS, and ORR vs placebo + FOLFIRI in VELOUR (with or without prior bevacizumab).
conventional_therapy
FDA-approved in combination with FOLFIRI for mCRC resistant to or progressed following an oxaliplatin-containing regimen (ZALTRAP section 1).
zaltrap, camptosar, FDA-DPD
Ramucirumab (CYRAMZA) + FOLFIRI second-line review (RAISE)
Improved OS and PFS vs placebo + FOLFIRI in RAISE.
conventional_therapy
FDA-approved in combination with FOLFIRI for mCRC with progression on or after prior bevacizumab, oxaliplatin, and a fluoropyrimidine (CYRAMZA section 1.3).
cyramza, camptosar, FDA-DPD
Second-line switched chemotherapy without anti-angiogenic (FOLFIRI, FOLFOX, or irinotecan)
Cytotoxic backbone switch when anti-angiogenic therapy is contraindicated.
conventional_therapy
FDA-approved irinotecan/5-FU/LV or oxaliplatin/5-FU/LV backbones when anti-VEGF/anti-EGFR agents are contraindicated or omitted.
camptosar, oxaliplatin, FDA-DPD, pdq_colon
Regorafenib (STIVARGA) monotherapy in refractory mCRC (CORRECT)
Statistically significant OS and PFS prolongation over placebo + BSC in CORRECT.
conventional_therapy
FDA-approved for mCRC previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy (STIVARGA section 1.1).
stivarga
Anti-EGFR therapy (cetuximab +/- irinotecan, or panitumumab) in anti-EGFR-naive RAS/BRAF-WT mCRC
Improved OS/PFS vs BSC in RAS/KRAS wild-type refractory mCRC (CA225-025, 20020408, 20100007, 20080763) and higher ORR with cetuximab + irinotecan vs cetuximab alone (BOND).
biomarker_selected_therapy
FDA-approved cetuximab (with irinotecan after irinotecan-based therapy or single-agent after irinotecan and oxaliplatin) and panitumumab monotherapy after fluoropyrimidine, oxaliplatin, and irinotecan in RAS wild-type mCRC.
erbitux, vectibix, camptosar
ctDNA-guided anti-EGFR rechallenge discussion in RAS/BRAF-WT mCRC (CRICKET / CHRONOS)
Objective responses observed in prospective phase 2 rechallenge cohorts lacking acquired RAS/BRAF/EGFR resistance mutations in plasma ctDNA.
biomarker_selected_therapy
Off-label rechallenge strategy supported by prospective phase 2 trials CRICKET (cetuximab + irinotecan) and CHRONOS (ctDNA-selected panitumumab); clinician sign-off pending.
pm_30476968, pm_35915157, erbitux, vectibix, camptosar